Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer-Reference-Cited by-同舟云学术

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer

Published:2017-04-15 Issue:2 Volume:49 Page:416-422
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Kim Miso,Keam Bhumsuk,Kim Tae-Min,Kim Hoon-Gu,Kim Jin-Soo,Lee Sung Sook,Shin Seong Hoon,Kim Min Kyoung,Park Keon Uk,Kim Dong-Wan,Yun Hwan Jung,Lee Jong Seok,Heo Dae Seog

Funder

Ministry of Food and Drug Safety

Korean Cancer Study Group

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://www.e-crt.org/upload/pdf/crt-2016-121.pdf

Reference20 articles.

1. Global cancer statistics, 2012

2. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012

3. Oesophageal carcinoma

4. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of irinotecan combined with raltitrexed or irinotecan monotherapy for salvage chemotherapy of esophageal squamous cell cancer: A prospective, open label, randomized phase II study;Cancer Medicine;2023-06-16

2. The role of PMI in evaluating the efficacy of PD-1 inhibitors and prognosis of patients treated for advanced esophageal squamous cell carcinoma;2023-05-10

3. Cisplatin-based combination therapy for cancer;Journal of Cancer Research and Therapeutics;2023

4. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma;Therapeutic Advances in Medical Oncology;2023-01

5. The development and progress of nanomedicine for esophageal cancer diagnosis and treatment;Seminars in Cancer Biology;2022-11